Valneva Vaccine Candidate Shows to Neutralize Omicron Variant
Valneva SE (NASDAQ: VALN), a specialty vaccine company, announced Thursday results from an initial laboratory study demonstrating that serum antibodies induced by three doses of Valneva’s inactivated COVID-19 vaccine candidate, VLA2001, neutralize the Omicron variant. 30 Participant Trial According to...